Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thymidylate synthase inhibitors.

P V Danenberg1, H Malli, S Swenson

  • 1Department of Biochemistry and Molecular Biology, USC/Norris Cancer Center, University of Southern California School of Medicine, Los Angeles, USA.

Seminars in Oncology
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).

ESMO open·2022
Same author

Accuracy and Clinical Utility of Reports from Outside Hospitals for CT of the Cervical Spine in Blunt Trauma.

AJNR. American journal of neuroradiology·2021
Same author

Studies on the mechanism of fluoropyrimidine cytotoxicity in l1210 cells: correlation with inhibition of thymidylate synthetase but not with incorporation into RNA.

Pharmaceutical research·2013
Same author

Review of influenza A virus in swine worldwide: a call for increased surveillance and research.

Zoonoses and public health·2013
Same author

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).

The pharmacogenomics journal·2012
Same author

TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.

The pharmacogenomics journal·2011

New antifolate drugs targeting thymidylate synthase (TS) offer improved cancer treatment strategies. These novel inhibitors, structurally similar to a natural TS substrate, aim to overcome limitations of 5-fluorouracil (5-FU).

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Thymidylate synthase (TS) is essential for DNA synthesis and cell proliferation.
  • 5-fluorouracil (5-FU) is a long-standing chemotherapy targeting TS, but its efficacy is limited.
  • New TS inhibitors are needed to improve cancer treatment outcomes.

Purpose of the Study:

  • To review the development and properties of novel TS inhibitory antifolates.
  • To explore new drug candidates targeting thymidylate synthase.
  • To summarize the clinical evaluation of new TS inhibitors.

Main Methods:

  • Review of existing literature on TS inhibitors.
  • Analysis of drug development stages and properties.
  • Comparison of novel antifolates with 5-FU.

Related Experiment Videos

Main Results:

  • Several novel TS inhibitory antifolates are in clinical trials (e.g., ZD1694, ZD9331, LY231514, BW1843U89, AG337, AG331).
  • These compounds differ in polyglutamylation and folate transport.
  • LY231514 exhibits secondary enzyme targets.

Conclusions:

  • New antifolates represent a promising class of anticancer drugs targeting TS.
  • Variations in drug properties suggest distinct antitumor activity and toxicity profiles.
  • Further research is warranted to optimize TS-targeted cancer therapies.